No takes yet. Share an insight, caveat, or question.
Analysis demonstrates enhanced selectivity of piperazinylalkyl analogs for dopamine receptors, suggesting new therapeutic avenues.
Choi et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: